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Abstract  
Introduction: Neurodegenerative disorders are involved in mortality and morbidity of every country. A high prevalence is estimated in Africa. 
Neurodegenerative disorders are defined by a progressive or self-limiting alteration of neurons implied in specific functional and anatomical 
functions. It encompasses a various range of clinical disorders from self-limiting to progressive. Focus on public health policies and scientific 
research is needed to understand the mechanisms to reduce this high prevalence. We use bibliometrics and mapping tools to explore the area 
studies and countries involved in scientific research on neurodegenerative disorders in Africa. Methods: We used two databases: Web of Science 
and Pubmed. We analyzed the journals, most cited articles, authors, publication years, organizations, funding agencies, countries and keywords in 
Web of Science Core collection database and publication years and Medical Subject Headings in Pubmed database. We mapped the data using 
VOSviewer. Results: We accessed 44 articles published between 1975 and 2014 in Web of Science Core collection Database and 669 from 
Pubmed database. The majority of which were after 2006. The main countries involved in research on neurodegenerative disorders in Africa the 
USA, the United Kingdom, France and South Africa representing the main network collaboration. Clinical neurology and Genetics hereditary are the 
main Web of Science categories whereas Neurosciences and Biochemistry and Molecular Biology are the main Web of Science categories for the 
general search "neurodegenerative disorders" not restrained to Africa. This is confirmed by Medical Subject Headings analysis from Pubmed with 
one more area study: Treatment. Conclusion: Neurodegenerative disorders research is leaded by South Africa with a network involving the USA, 
the UK, as well as African countries such Zambia. The chief field that emerged was on patient and hereditary as well as treatment. Public health 
policies were lacking fields in research whereas prevalence is estimated to be important in every country. New 17 sustainable development goals of 
the United Nations could help in this way. 
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Introduction 
 
Neurodegenerative disorders (ND) encompass various pathologies 
from well-identified genetic abnormalities such as Huntington's 
disease [1] to multifactorial mechanisms such as Parkinson disease 
or Alzheimer disease [2-3]. ND are characterized by a progressive 
dysfunction of the central nervous system. Definitions of 
neurodegeneration can be multiple and we define it in this paper as 
a progressive or self-limiting alteration of neurons implied in specific 
functional and anatomical functions [4]. Nevertheless, clinical 
findings of ND are not only neurologic and can also be 
multisystemic, it means with dysfunctions of other organs such as in 
Huntington's disease [5]. Prevalence of neurodegenerative disorders 
is very high. For example, in Europe, only Parkinson disease is 
estimated from 65.6 per 100,000 to 12,500 per 100,000 inhabitants 
[6]. Costs are huge; estimation in 2004 in Europe is 386 billion 
euros [7]. Neurodegenerative disorders are involved in mortality and 
morbidity of every country. A high prevalence is estimated in Africa 
[8]. Focus on public health policies and scientific research is needed 
to understand the mechanisms to reduce this prevalence. In order 
to focus on a Africa-relevant approach, I will study both progressive 
and self-limiting neurodegenerative disorders, including, for example 
Nodding Syndrome (progressive) and cassavism, lathyrism (self-
limiting). All of these disorders have been and are likely to continue 
to be endemic/epidemic regionally in Africa [9-10]. The aim of this 
article is to analyze scientific publications on neurodegenerative 
disorders in Africa and to determine the links between the countries 





We used previously described methods [11-12]. In brief, we 
accessed through two databases: the Science Citation Index-
Expanded (SCIE) database Core collection, from the Web of Science 
(WOS) platform Thomson Reuters and Pubmed database. 
Concerning the WOS database, in the advanced search from WOS, 
we obtained the articles using this formula: TS=(Neurodegenerative 
disorders AND Africa) for the period 1975-2014. We verified each 
record to ensure its relevance. There were no restrictions regarding 
the document types. Then, we performed the “analysis results” 
function of WOS. We extracted: journals, most cited articles, 
authors, countries, funding agencies, organizations, publication 
years and Web of Science Categories. In order to evaluate the 
research networks between countries, after the analysis by country, 
we viewed the records of each country and then performed the 
analysis a second time in order to understand the links between the 
chosen country and the other countries. We then established the 
mapping diagram. To analyze the Web of Science Categories, we 
exported the date into a file “analyze.txt”. This file can be read by 
the program wc10.exe. It generated map-files for VOSviewer [12-
14]. These analyses were to compare with the same search but 
without “Africa”. It means we performed the search 
TS=Neurodegenerative in WOS database. We added search of 
another database: Pubmed, to extend the results of the WOS 
database. We obtained publications using this formula: 
(Neurodegenerative disorders AND Africa) AND ("1900"(Date - 
Publication): "2014/12/31"(Date - Publication)). We extracted 
publication years. We extracted data with MEDLINE file. We then 
analyzed Medical Subject Headings (MeSH) with previously method 
described. We generated VOS-viewer picture as described [12-14]. 
The WOS core collection database and Pubmed database were used 
to perform our study. Publications from African countries could be 





Using WOS core collection database, we obtained 44 records. More 
than 68% of the records were after 2006 (Table 1). The four 
authors with most records were Van Staden (South Africa), 
Aderogba (South Africa), Krausen (South Africa) and Ndhlala (South 
Africa). The main journals were European Journal of Human 
Genetics (6,8%), Journal of Ethnopharmacology (6,8%), African 
Journal of Biotechnology (4,5%), Journal of the Neurological 
Sciences (4,5%), Movement disorders (4,5%), South African 
Medical Journal (4,5%). The main research funding agencies were 
the University of Kwazulu-Natal (South Africa) (6,8%), UK Parkinson 
disease Society (4,5%), The University of Cape Town Research 
Council (South Africa) (4,5%) and the National Research Fundation 
(South Africa) (4,5%). The four most represented institutions were 
the University of Cape-Town (11,3%), INSERM (French Institute of 
Health and Medical Research, France) (9%), the University of 
Kwazulu-Natal (South Africa) (9%), The University of Witwatersrand 
(South Africa) (9%). The main countries involved were South Africa 
(31,8%), the United States of America (29,5%), the United Kingdom 
(18,18%), France (11,3%), Australia (6,8%), Canada (6,8%) and 
Italy (6,8%). We presented the countries involved according to the 
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percentage of publications found in WOS database (Figure 1). Then, 
we mapped the networks between the main countries (Figure 2). 
The scientific network concerning research on neurodegenerative 
disorders, with the main countries involved, is described. The main 
arrow/link is between the USA, the United Kingdom and South 
Africa as the most important collaboration. Others networks are 
involved with France, Canada, Japan, Italy, the Netherlands and 
African countries such as Zambia, Morocco, Togo and Benin. Finally, 
we used VOSviewer to map the Web of Science Categories (Figure 
3). The most important categories were Clinical neurology and 
Genetics Heredity. We compare it to the map of the search 
“neurodegenerative disorders” without restraining to Africa (Figure 
4). The most important categories were Neurosciences and 
Biochemistry Molecular Biology in that case, showing differences 
between publications specifically focused on Africa or on 
neurodegenerative disorders in general. We then compared the data 
from WOS database with another database: Pubmed. We extracted 
669 publications. We presented the publication years and 38% were 
after 2006 (Figure 2). This result is concordant with WOS database. 
Moreover, more publications were found in percentage before 2006, 
and first publications were in the 1960s. We extracted the Medical 
Subject Headings (MeSH), and we mapped with VOSviewer (Figure 
5). The main MeSH are patient, mutation, neurodegenerative 
disorder and treatment. The first MeSH are concordant with WOS 
categories (Figure 3): patient, mutation, and neurodegenerative 
disorder with Clinical neurology and Genetics Heredity. We also 






The results of our analysis of two databases present a majority of 
publications after 2006 (Table 1 and Table 2). Pubmed database 
allow us to say that studies on neurodegenerative disorders in Africa 
were performed decades ago [15]. Neurodegenerative disorders are 
therefore a burning issue for the African continent. 
 
The increase of publications after 2006 is concordant with the 
general increase of publications in these two databases. 
Nevertheless the general volume of publications is very low. In fact, 
only with the example of WOS database, 44 publications were found 
with the search “neurodegenerative disorders AND Africa” whereas 
we found more than 24000 publications with the search 
“Neurodegenerative disorders” without restraining to Africa. It 
represents only 0, 18% of the publications of this fields of research. 
It means that the area studies are different if we restrain or not to 
Africa. According to Figure 2 and Figure 3, research in Africa 
appears to be focused on clinics. The goal is therefore to perform 
the diagnosis which seems under diagnosed [8; 16-17]. Moreover, 
different disease-specific hotspots can be determined. 
 
To discuss these results, I will focus on the distinction between 
progressive and self-limiting disorders. Self-limiting neurological 
disorders can be defined as presence of neurological dysfunction 
with permanent or regressive state but without progression of the 
neurological alterations. The search “Neurodegenerative disorders” 
without Africa focuses on progressive disorders with for example 
Alzheimer's disease, Huntington's disease or Parkinson's disease. In 
the case of the search on Africa, a self-limiting disease-specific 
hotspot is emerging. The main example is about cassavism and 
lathyrism [10]. These diseases are caused by a high exposure to 
cassava roots for the first one and grass pea for the second one. 
Clinical features are not distinguishable between both diseases and 
consist in spastic paraparesis and crippling disability. This specific 
field of research on neurodegenerative disorders and Africa is 
described by a most prominent field of research in toxicology as well 
as the clinical neurology field (Figure 3). In these cases, prevention 
is therefore possible. The patients are known to be the poorest 
section of the population [10]. Education and fighting against 
illiteracy are necessary. Moreover, genetically modified crops could 
be used to avoid cassavism and lathyrism. Self-limiting neurological 
disorders are therefore an African specific hotspot. 
 
Progressive disorders are also a main issue for Africa with also 
specific diseases. Three main examples of progressive disorders 
found in Africa and other continents can be developed: Parkinson's 
disease, Alzheimer's disease and Huntington's disease. The first one 
results in dopamine deficiency within the basal ganglia and leads to 
slowly progressive motor impairments. Management is possible but 
as the aetiology and pathogenesis are complex and not well 
understood, Parkinson's disease treatments are not fully sufficient 
[2]. Concerning Alzheimer's disease, it is due to amyloid plaques 
leading to dementia. As the first one, the aetiology and 
pathogenesis remain unclear, therefore management of patient is 
very difficult [3]. For the third one, Huntington's disease, it is 
caused by a polyglutamine stretch in the gene Huntingtin. The 
clearly genetic abnormality results in the expression of less normal 
protein and the production of a mutant protein. Clinical features are 
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chorea, motor and psychiatric impairments and it occurs as the age 
of 30-35 years old. It is a progressive disorder leading to death. 
There is no treatment [1]. For these examples of progressive 
neurological disorders, African countries propose the management 
of the patients [16-17]. It means that a structure is needed with 
physicians trained for diagnosis, predictive genetic testing in the 
case of some neurodegenerative disorders as Huntington's disease, 
and follow-up. South Africa is the main country involved in such 
action [18]. That's why we found in our analysis that the main 
institutions and the main founding agencies were South African. 
Nevertheless, number of structures and physicians remain not 
sufficient. The World Health Organization notes that Africa has the 
lowest median number of neurological beds per 10 000 population 
and the lowest number of neurologists per 100000 population [19]. 
Therefore, in the fight against progressive neurological disorders, 
collaboration and networks are needed. We didn't find for example a 
main network between African countries (Figure 2). This last point is 
problematic as in the case of progressive disorders, some diseases 
appear to be endemic to Africa as Nodding syndrome [9]. Patients 
are found in Uganda, Tanzania, Liberia and Sudan. Clinical signs 
consist in involuntary dropping of the head. Other signs as seizure 
are associated. No aetiology has been yet known. There is no 
treatment. 
 
If a main African collaboration network is needed, international 
networks are also necessary. The USA and the UK, as well as France 
are present in both fields of research on self-limiting and 
progressive neurological disorders. But, we already present that 
neurodegenerative disorders are not, for instance, one of the main 
public health policies in Africa except for HIV-related progressive 
neurological disorders [10-11]. Millennium development goals were 
not focused on neurodegenerative disorders. HIV, malaria, 
tuberculosis are clearly mentioned and the policies on fighting these 
diseases were funded but progressive neurodegenerative disorders 
such as Parkinson, Alzheimer and other diseases and self-limiting 
neurological disorders are not mentioned [20]. 
 
The United Nations Sustainable Development Summit on 25 
September 2015 proposed 17 sustainable development goals. The 
goal number 3 is entitled “Good health and well-being”. Therefore, 
neurodegenerative disorders are clearly involved in this topic, as a 
non-communicable disease. The African continent with a huge 
prevalence of neurodegenerative disorders [8] could benefit from 
the experiences of networks on research, therapeutic trials, follow-






In conclusion, neurodegenerative disorders are a main burning issue 
for the future of Africa. South Africa remains the leader in this field. 
Nevertheless, an increase of structures, physicians, collaborations is 
needed with a clear public health policy focused on 
neurodegeneration. 
 
What is known about this topic 
 Neurodegenerative disorders are involved in mortality and 
morbidity of every country; 
 High prevalence of neurodegenerative disorders is 
estimated in Africa; 
 Both progressive and self-limiting neurodegenerative 
disorders are present in Africa. 
 
What this study adds 
 Neurodegenerative disorders research is leaded by South 
Africa with a network involving the USA, the UK, as well 
as African countries such Zambia; 
 The chief field that emerged was on patient and 
hereditary as well as treatment; 
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Table 1: Records (n=44, WOS database) per year 







2014 8 18,182 
2013 4 9,091 
2012 7 15,909 
2011 2 4,545 
2010 3 6,818 
2009 3 6,818 
2008 1 2,273 
2007 1 2,273 
2006 1 2,273 
2005 1 2,273 
2004 2 4,545 
2000 1 2,273 
1999 3 6,818 
1998 3 6,818 
1997 1 2,273 
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2014 62 9,012 1989 8 1,163 
2013 5 0,727 1988 12 1,744 
2012 52 7,558 1987 7 1,017 
2011 41 5,959 1986 9 1,308 
2010 4 0,581 1985 4 0,581 
2009 4 0,581 1984 7 1,017 
2008 42 6,105 1983 3 0,436 
2007 17 2,471 1982 4 0,581 
2006 34 4,942 1981 5 0,727 
2005 19 2,762 1980 6 0,872 
2004 26 3,779 1979 5 0,727 
2003 28 4,070 1978 2 0,291 
2002 22 3,198 1977 3 0,436 
2001 24 3,488 1976 1 0,145 
2000 21 3,052 1975 1 0,145 
1999 26 3,779 1974 2 0,291 
1998 15 2,180 1973 5 0,727 
1997 22 3,198 1972 8 1,163 
1996 18 2,616 1971 1 0,145 
1995 17 2,471 1970 4 0,581 
1994 16 2,326 1969 3 0,436 
1993 16 2,326 1967 2 0,291 
1992 15 2,180 1966 2 0,291 
1991 11 1,599 1964 3 0,436 
1990 5 0,727 


















Figure 1: Countries involved in neurodegenerative disorders research in Africa according to the percentage of 
publications in WOS database. The United States of America (USA), the United Kingdom (UK), South Africa and 




Figure 2: Publication collaboration networks between the countries involved in neurodegenerative disorders research 
in Africa, according to WOS database. The main network is between South Africa, US and UK  
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Figure 3: Web of Science categories for the search “Neurodegenerative disorders AND Africa”. The main categories are 





Page number not for citation purposes 10 
Figure 4: Web of Science categories for the search “Neurodegenerative disorders”. The main categories are Neurosciences 





Figure 5: Medical Subject Headings (MeSH) of the search “Neurodegenerative disorders AND Africa” in Pubmed database. The main MeSH 
are patient, mutation, neurodegenerative disorder and treatment 
 
